The Advent of More Potent ALK Inhibitors
Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.
Clinical Pearls
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors and the treatment of ALK-positive lung cancer patients with crizotinib.
- The treatment of these patients is more complicated now, with the advent of more potent ALK inhibitors
- New ALK inhibitors are potent in patients both resistant and naive to crizotinib
- At a large cancer center, the option exists to start crizotinib as standard therapy or consider a clinical trial with a next-generation ALK inhibitor
- In the community setting, standard procedure would be to start a newly-diagnosed ALK-positive patient on crizotinib
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
